NeoGenomics, Inc. (NEO)
| Market Cap | 4.56B |
| Revenue (ttm) | 453.95M |
| Net Income (ttm) | -10.96M |
| Shares Out | 116.20M |
| EPS (ttm) | -0.10 |
| PE Ratio | n/a |
| Forward PE | 222.22 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 13 |
| Last Price | $36.81 |
| Previous Close | $37.88 |
| Change ($) | -1.08 |
| Change (%) | -2.84% |
| Day's Open | 38.35 |
| Day's Range | 36.30 - 38.82 |
| Day's Volume | 876,156 |
| 52-Week Range | 25.19 - 61.57 |
Spotting bloated toxic stocks on a regular basis and abandoning them at the right time is one of the secrets to a winning investment strategy.
FT. MYERS, FL / ACCESSSWIRE / May 10, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced...
These under-the-radar names deserve investors' attention.
NeoGenomics (NEO) delivered earnings and revenue surprises of -500.00% and 2.62%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
NeoGenomics Inc (NASDAQ: NEO) has agreed to acquire the remaining stake in Inivata Ltd, a commercial-stage liquid biopsy platform company headquartered in England. The acquisition follows a $25 million ...
First-Quarter 2021 Results and Highlights: Consolidated revenue increased 9% to $116 million Clinical Services revenue increased 4% to $96 million Pharma Services revenue increased 46% to $19 million Co...
Establishes NeoGenomics as a technology leader in the minimal residual disease (MRD) testing market NeoGenomics exercises option struck in May 2020 to purchase remaining equity stake for $390 million Co...
NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SGT Program will provide KRAS G12C testing to eligible patients at no cost, regardless of insurance type. FT. MYERS, FL / ACCESSWIRE / April 19, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider...
FT. MYERS, FL / ACCESSWIRE / April 13, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announce...
FT MYERS, FL / ACCESSWIRE / April 7, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing and global contract research services, announced today that it plans to r...
NeoGenomics (NEO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Clinical Decision Support to Enable Precision Oncology FT. MYERS, FL / ACCESSWIRE / March 24, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and glo...
Clinical Trial Matching Collaboration Will Enhance Identification of Patients with Any Solid Tumo r Harboring an NRG1 Gene Fusion Identified Using NeoGenomics' Advanced Gene Fusion Panels FORT MYERS, FL...
FT. MYERS, FL / ACCESSWIRE / March 1, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced...
Shares of NeoGenomics (NASDAQ:NEO) were unchanged after the company reported Q4 results. Quarterly Results Earnings per share rose 40.00% over the past year to $0.14, which beat the estimate of $0.06.
NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The S&P 500 Index stocks saw their aggregate trailing 12-month revenue per share increase at a compound average growth rate (CAGR) of 2% per annum over the past five years. The share price of the index ...
Access to industry-leading genomic database and real-world evidence designed to optimize trial design, site selection, clinical trial matching and translational research Access to industry-leading genom...
FORT MYERS, FL / ACCESSWIRE / January 6, 2021 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of cancer-focused genetics testing services and global oncology contract research servi...
FORT MYERS, FL / ACCESSWIRE / January 5, 2021 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of cancer-focused genetics testing services and global oncology contract research servi...
FT. MYERS, FL / ACCESSWIRE / January 4, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announc...
TipRanks analyst ranking service pinpoints Wall Street's best-performing stocks, like Costco and Twitter
NeoGenomics remains insulated and differentiated from peers via a plethora of offerings in clinical diagnostics, as a potential market-leader in oncology services. The growth vision looks at consolidati...
NeoGenomics, Inc.'s (NEO) CEO Doug VanOort on Q3 2020 Results - Earnings Call Transcript
NeoGenomics (NEO) delivered earnings and revenue surprises of 500.00% and -2.69%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NeoGenomics (NEO) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
ANIK vs. NEO: Which Stock Is the Better Value Option?
The oncology reference lab never stopped investing in near- and long-term opportunities. It expects that to pay off -- and soon.
NeoGenomics, Inc. (NEO) CEO Doug VanOort on Q2 2020 Results - Earnings Call Transcript
Shares of NeoGenomics (NASDAQ:NEO) rose 1% after the company reported Q2 results.
NeoGenomics (NEO) delivered earnings and revenue surprises of 55.56% and 1.01%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
These pioneers will be winners however the pandemic plays out.
NeoGenomics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 81. The post NeoGenomics Shows Market Leadership With Jump To 81 RS Rating appeared first on...
A Relative Strength Rating upgrade for NeoGenomics shows improving technical performance. Will it continue?
Near-term headwinds won’t damage the long-term prospects of these two companies.
The company decided to pull the trigger on a combined offering of stock and debt to pad its balance sheet during uncertain times.
Despite experiencing a double-digit decline in test volumes, the cancer genetics lab hasn't furloughed employees. It has even retooled labs to process COVID-19 swab and blood tests.
Neogenomics Inc. (NEO) CEO Doug VanOort on Q1 2020 Results - Earnings Call Transcript
NeoGenomics (NEO) delivered earnings and revenue surprises of -200.00% and -0.02%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Test volumes fell by double digits at the end of March compared with the year-ago period. How long does management think that trend will continue?
Investors should prepare for the genetic testing industry to see a tangible slowdown in volumes due to the coronavirus pandemic.
Growth stocks have been getting punished in the current market downturn, but investors with a long-term mindset will find plenty to like in the latest earnings report.
Advances in precision medicine continue to propel the leader in oncology testing services.
The cancer genetics company reported full-year 2019 operating results, but that's probably not the reason for the decline.
NeoGenomics, Inc. (NEO) CEO Doug VanOort on Q4 2019 Results - Earnings Call Transcript
NeoGenomics (NEO) delivered earnings and revenue surprises of 42.86% and 2.31%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
About NEO
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates in two segments, Clinical Services and Pharma Services. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or... [Read more...]
| Industry Diagnostics & Research | IPO Date Nov 2, 1999 |
| Stock Exchange NASDAQ | Ticker Symbol NEO |
Financial Performance
In 2020, NeoGenomics's revenue was $444.45 million, an increase of 8.71% compared to the previous year's $408.83 million. Earnings were $4.17 million, a decrease of -47.89%.
Analyst Forecasts
According to 11 analysts, the average rating for NeoGenomics stock is "Strong Buy." The 12-month stock price forecast is 60.00, which is an increase of 63.02% from the latest price.